LadRx Corporation is a biopharmaceutical firm focused on identifying and advancing treatments for cancer patients. Its primary drug candidate, aldoxorubicin, which is a modified variant of the anti-cancer medication doxorubicin, is currently in late-stage clinical assessment. Additionally, the company possesses a pipeline of preclinical therapeutics, including linker activated drug releases (LADRs) numbered 7, 8, 9, and 10, all designed to target cancerous cells. Founded in 1985, this Los Angeles, California-based company adopted its current name, LadRx Corporation, in September 2022, having previously operated as CytRx Corporation.


Net sales
Gross margin
Net income